None listed
Conditions
Interventions
None listed
Sponsors
Hanyang University Seoul Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who receive mepolizumab for treatment among patients with severe asthma, and severe asthma is defined as one or more of the following: 1) Patients with poor asthma control despite receiving step 4 or step 5 treatment according to the definition of the GINA guideline 2) Even if it is controlled well while receiving step 4 or step 5 treatment at the time of the investigation, it falls under one or more of the following cases: (a) Visiting an emergency room, hospitalization or outpatient due to asthma exacerbation at least once a year; (b) systemic steroids are required at least three times a year (at 15 mg/day per prednisolone for at least three days); (c) Immediately asthma worsens when oral or ICS dose is reduced by less than 25%; (d) If you have had a very fatal asthma attack in the past (in intensive care or intubation)
Exclusion criteria
Exclusion criteria: (1) bronchiectasis (except mild) (2) TB destroyed lung (3) interstitial lung disease (4) chronic respiratory disease other than asthma (Tuberculosis, active infectious disease, etc.) (5) severe psychiatric disorders that can impair research, such as schizophrenia (6) severe congestive heart failure (7) Other serious systemic diseases (ESRD on hemodialysis, severe liver disease) (8) continuous systemic steroid user due to other disease control (9) If the life expectancy is less than 3 years due to malignancy (patients in remission for =5 years could be included)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reaction | — |
Secondary
| Measure | Time frame |
|---|---|
| severe adverse reaction | — |
Countries
Korea, Republic of
Contacts
Public ContactSo-Young Park
Chung-Ang University Gwangmyeong Hospital
Outcome results
None listed